Summit Therapeutics Expands Global Oncology Footprint with Phase II/III HARMONi-GU1 Trial of Ivonescimab in Advanced Urothelial Carcinoma
Executive Overview In a significant strategic expansion of its oncology clinical development pipeline, Summit Therapeutics has announced the initiation of the global, multi-regional Phase II/III HARMONi-GU1 clinical trial. This landmark…